clinical trial · NCT06287450
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
Shenzhen Shenxin Biotechnology Co., Ltd·phase1·not yet recruiting·n = 200
Respiratory Syncytial Virus InfectionsBivalent RSV Vaccine (IN006)Placebo
brief summary
The study will evaluate the safety, tolerability, and immunogenicity of a single injection of up to 4 dose levels of IN006 in younger adults and 3 dose levels of IN006 in older adults; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults.
started
Dec 1, 2026
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Apr 13, 2026
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol